Be the first person to write a business review for Streck, Inc.

SurModics, Inc. Company was founded in 1979 and is headquartered in Eden Prairie, Minnesota. SurModics, Inc. engages in the development, manufacture, and sale of surface modification and drug delivery technologies to the healthcare industry. The company operates through four business units: Cardiovascular, Ophthalmology, SurModics Pharmaceuticals, and In Vitro Technologies. The Cardiovascular business unit supports the drug delivery and surface modification needs of cardiovascular customers by providing drug delivery polymers and coating technologies, including advanced lubricity (slippery) coatings that ease placement and maneuverability of medical devices in the body. The Ophthalmology business unit develops drug delivery systems for various drugs and other bioactive agents developed by pharmaceutical and ophthalmology companies for the treatment of serious eye diseases.The SurModics Pharmaceuticals business unit specializes in proprietary injectable microparticles and implants based on biodegradable polymers to provide sustained delivery of drugs, as well as supplies biodegradable polymers to corporate and academic customers. The In Vitro Technologies business unit specializes in in vitro diagnostic products and technologies for the biomedical research and medical diagnostic markets. Its products and technologies include protein stabilization reagents, substrates, recombinant autoimmune antigens, surface chemistry technologies for nucleic acid and protein immobilization, and diagnostic format intellectual property. The company markets its technologies and products through sales professionals, as well as sales and marketing relationships with third-parties worldwide. It has collaboration agreements with Genzyme Corporation to develop novel drug delivery solutions with an initial focus on peptide delivery.

Synbiotics is concerned with the conditions of cats, cows, canines, and other critters. The company provides diagnostic products for the animal health care industry worldwide, through facilities in the US and France. Its canine reproduction services division trains vets in canine reproductive services, including artificial insemination, and runs the Canine Freezing Center Network, which operates what Synbiotics says is the largest bank of frozen canine semen in the world. Synbiotics company also develops and markets test kits for animal parasites, pregnancy, viruses, and other diseases and conditions in the animal kingdom. Its test for bird flu, the FluDetect Avian Influenza Type A antigen kit, is sold globally.

Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. It has a global partnership with Roche for developing novel CRACM inhibitors, an oral calcium released activated calcium modulator ion channel inhibitor program that is in the lead optimization stage for the treatment of autoimmune diseases. The company also retains rights in various indications and markets to its other drug candidates and programs, which include STA-9090, an Hsp90 inhibitor that is in Phase 1 development; elesclomol, an oxidative stress inducer for the treatment of cancer; and apilimod, an oral IL-12/23 inhibitor, which is in Phase 2 for rheumatoid arthritis. In addition, Synta Pharmaceuticals Corp. is developing STA-9584, a vascular disrupting agent that is in preclinical development. The company was incorporated in 2000 and is based in Lexington, Massachusetts.

Tetracore, Inc. company's FDA-approved Redline lab test can distinguish anthrax bacteria from similar microorganisms. Other bioterrorism countermeasures the firm offers include the BioThreat Alert testing kit used by first responders to detect various biological toxins including botulinum toxin (botulism) and staphylococcus aureus enterotoxin B (SEB). Tetracore also sells veterinary diagnostic (VetAlert) tests for foot-and-mouth disease, West Nile, and other diseases, and it markets antibodies (proteins) for use by research labs.

Third Wave Technologies is riding the biotech breakers. Using its Invader technology, Third Wave develops molecular diagnostic tests that detect genetic variations associated with a variety of conditions, including cystic fibrosis, cardiovascular risk factors, and infectious disease. Some tests can determine a patient's likely response to certain drugs, making it possible for doctors to avoid prescribing a drug that might cause dangerous side effects. Third Wave company has a strong presence in Japan, where it has a collaboration agreement with genetic researchers at the University of Tokyo. Third Wave Technologies was acquired by Hologic in 2008 for $580 million.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.